Sponsored Content
Developability: Evaluating Specificity, Immunogenicity, Functionality, and Manufacturability for Lead Candidate Selection
BPI Contributor
May 31, 2019
20 Min View
Date: May 31, 2019
Duration: 20 Min
Already have an account?
Sponsored by Abzena
This webcast features: Campbell Bunce, Chief Scientific Officer, Abzena
Developability assessment is based on multiple readouts that capture the fundamental characteristics of successful drug design: specificity, functionality, safety and manufacturability.
Developability assessment can severely reduce the time and expenditure required to take multiple lead candidates through expensive cell line development and manufacturing runs when the molecule has inherent liabilities that will inhibit its progress.
Why do it:
Identify liabilities and risk factors in drug candidates early in the development process
Scope to apply design alterations to fix/reduce liabilities
Select the best drug candidate(s) for development
Reduces risk and expenditure on later costly stages of development: production cell line generation and manufacture
What to expect from it:
Drug candidates ranked across multiple parameters
Establish and implement a plan to adjust drug design early in the process to mitigate risks
Lead candidate identified for manufacture with minimized cost and risk profile
Watch the recorded webcast below.
About the Author
You May Also Like
Sponsored Content
Jun 5 - Jun 6, 2024
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More
